Roger B. Ruggeri
Research Subjects
Roger B. Ruggeri has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Chris Limberakis
Pfizer Worldwide Research, Development, and Medical, Groton, Connecticut 06340, United States
5 shared publications - David W. Piotrowski
Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States
4 shared publications - David A. Griffith
Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States
3 shared publications - Scott W. Bagley
Medicine Design, Pfizer Inc, Groton, USA
3 shared publications Steven B. Coffey
Pfizer Medicine Design, Groton, CT 06340, United States
3 shared publicationsAlan M. Mathiowetz
Pfizer Medicine Design, Cambridge, MA 02139, United States
2 shared publications
Latest Publications
- 15 August 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 94, 129454
6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor
- 15 August 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 94, 129454
6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor
- 26 June 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 92, 129394
Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups
- 26 June 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 92, 129394
Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups
- Open Access
- 28 April 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (20) , 11173-11184
Bioorthogonal Tethering Enhances Drug Fragment Affinity for G Protein-Coupled Receptors in Live Cells
G protein-coupled receptors (GPCRs) modulate diverse cellular signaling pathways and are important drug targets. Despite the availability of high-resolution structures, the discovery of allosteric modulators remains challenging due to the dynamic nature of GPCRs in native membranes. We developed a strategy to covalently tether drug fragments adjacent to allosteric sites in GPCRs to enhance their potency and enable fragment-based drug screening in cell-based systems. We employed genetic code expansion to site-specifically introduce noncanonical amino acids with reactive groups in C-C chemokine receptor 5 (CCR5) near an allosteric binding site for the drug maraviroc. We then used molecular dynamics simulations to design heterobifunctional maraviroc analogues consisting of a drug fragment connected by a flexible linker to a reactive moiety capable of undergoing a bioorthogonal coupling reaction. We synthesized a library of these analogues and employed the bioorthogonal inverse electron demand Diels-Alder reaction to couple the analogues to the engineered CCR5 in live cells, which were then assayed using cell-based signaling assays. Tetherable low-affinity maraviroc fragments displayed an increase in potency for CCR5 engineered with reactive unnatural amino acids that were adjacent to the maraviroc binding site. The strategy we describe to tether novel drug fragments to GPCRs should prove useful to probe allosteric or cryptic binding site functionality in fragment-based GPCR-targeted drug discovery.
- 28 April 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (20) , 11173-11184
Open AccessBioorthogonal Tethering Enhances Drug Fragment Affinity for G Protein-Coupled Receptors in Live Cells
G protein-coupled receptors (GPCRs) modulate diverse cellular signaling pathways and are important drug targets. Despite the availability of high-resolution structures, the discovery of allosteric modulators remains challenging due to the dynamic nature of GPCRs in native membranes. We developed a strategy to covalently tether drug fragments adjacent to allosteric sites in GPCRs to enhance their potency and enable fragment-based drug screening in cell-based systems. We employed genetic code expansion to site-specifically introduce noncanonical amino acids with reactive groups in C-C chemokine receptor 5 (CCR5) near an allosteric binding site for the drug maraviroc. We then used molecular dynamics simulations to design heterobifunctional maraviroc analogues consisting of a drug fragment connected by a flexible linker to a reactive moiety capable of undergoing a bioorthogonal coupling reaction. We synthesized a library of these analogues and employed the bioorthogonal inverse electron demand Diels-Alder reaction to couple the analogues to the engineered CCR5 in live cells, which were then assayed using cell-based signaling assays. Tetherable low-affinity maraviroc fragments displayed an increase in potency for CCR5 engineered with reactive unnatural amino acids that were adjacent to the maraviroc binding site. The strategy we describe to tether novel drug fragments to GPCRs should prove useful to probe allosteric or cryptic binding site functionality in fragment-based GPCR-targeted drug discovery.
- 23 December 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (1) , 460-472
Discovery of High-Affinity Small-Molecule Binders of the Epigenetic Reader YEATS4
A series of small-molecule YEATS4 binders have been discovered as part of an ongoing research effort to generate high-quality probe molecules for emerging and/or challenging epigenetic targets. Analogues such as 4d and 4e demonstrate excellent potency and selectivity for YEATS4 binding versus YEATS1,2,3 and exhibit good physical properties and in vitro safety profiles. A new X-ray crystal structure confirms direct binding of this chemical series to YEATS4 at the lysine acetylation recognition site of the YEATS domain. Multiple analogues engage YEATS4 with nanomolar potency in a whole-cell nanoluciferase bioluminescent resonance energy transfer assay. Rodent pharmacokinetic studies demonstrate the competency of several analogues as in vivo-capable binders.
- 23 December 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (1) , 460-472
Discovery of High-Affinity Small-Molecule Binders of the Epigenetic Reader YEATS4
A series of small-molecule YEATS4 binders have been discovered as part of an ongoing research effort to generate high-quality probe molecules for emerging and/or challenging epigenetic targets. Analogues such as 4d and 4e demonstrate excellent potency and selectivity for YEATS4 binding versus YEATS1,2,3 and exhibit good physical properties and in vitro safety profiles. A new X-ray crystal structure confirms direct binding of this chemical series to YEATS4 at the lysine acetylation recognition site of the YEATS domain. Multiple analogues engage YEATS4 with nanomolar potency in a whole-cell nanoluciferase bioluminescent resonance energy transfer assay. Rodent pharmacokinetic studies demonstrate the competency of several analogues as in vivo-capable binders.
- Top Cited PapersOpen Access
- 1 June 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (12) , 8208-8226
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited because they require injection. Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1R agonist PF-06882961 (danuglipron). A sensitized high-throughput screen was used to identify 5-fluoropyrimidine-based GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nanomolar potency. Incorporation of a carboxylic acid moiety provided considerable GLP-1R potency gains with improved off-target pharmacology and reduced metabolic clearance, ultimately resulting in the identification of danuglipron. Danuglipron increased insulin levels in primates but not rodents, which was explained by receptor mutagensis studies and a cryogenic electron microscope structure that revealed a binding pocket requiring a primate-specific tryptophan 33 residue. Oral administration of danuglipron to healthy humans produced dose-proportional increases in systemic exposure (NCT03309241). This opens an opportunity for oral small-molecule therapies that target the well-validated GLP-1R for metabolic health.
- 1 June 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (12) , 8208-8226
Top Cited PapersOpen AccessA Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited because they require injection. Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1R agonist PF-06882961 (danuglipron). A sensitized high-throughput screen was used to identify 5-fluoropyrimidine-based GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nanomolar potency. Incorporation of a carboxylic acid moiety provided considerable GLP-1R potency gains with improved off-target pharmacology and reduced metabolic clearance, ultimately resulting in the identification of danuglipron. Danuglipron increased insulin levels in primates but not rodents, which was explained by receptor mutagensis studies and a cryogenic electron microscope structure that revealed a binding pocket requiring a primate-specific tryptophan 33 residue. Oral administration of danuglipron to healthy humans produced dose-proportional increases in systemic exposure (NCT03309241). This opens an opportunity for oral small-molecule therapies that target the well-validated GLP-1R for metabolic health.
- Open Access
A small-molecule oral agonist of the human glucagon-like peptide-1 receptor
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited by the requirement for injection. Here we describe the first effective, orally bioavailable small molecule GLP-1R agonists. A sensitized high-throughput screen identified a series of small molecule GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nM potency. These small molecule agonists increased insulin levels in primates but not rodents, which is explained by a cryo-EM structure that revealed a binding pocket requiring primate-specific tryptophan 33. Importantly, oral administration of agonist PF-06882961 to healthy humans produced dose-dependent declines in serum glucose ( NCT03309241 ). This opens the door to a new era of oral small molecule therapies that target the well-validated GLP-1R pathway for metabolic health. One Sentence Summary: PF-06882961 is an orally administered small molecule that activates the GLP-1 receptor to lower blood glucose in humans.
Open AccessA small-molecule oral agonist of the human glucagon-like peptide-1 receptor
Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized diabetes therapy, but their use has been limited by the requirement for injection. Here we describe the first effective, orally bioavailable small molecule GLP-1R agonists. A sensitized high-throughput screen identified a series of small molecule GLP-1R agonists that were optimized to promote endogenous GLP-1R signaling with nM potency. These small molecule agonists increased insulin levels in primates but not rodents, which is explained by a cryo-EM structure that revealed a binding pocket requiring primate-specific tryptophan 33. Importantly, oral administration of agonist PF-06882961 to healthy humans produced dose-dependent declines in serum glucose ( NCT03309241 ). This opens the door to a new era of oral small molecule therapies that target the well-validated GLP-1R pathway for metabolic health. One Sentence Summary: PF-06882961 is an orally administered small molecule that activates the GLP-1 receptor to lower blood glucose in humans.
- 1 October 2012
- Published by Elsevier in Tetrahedron Letters
- Vol. 53 (41) , 5467-5470
1,4-Addition of an aryllithium reagent to diethyl ketomalonate. Scalable synthesis of ethyl 1-(hydroxymethyl)-1,3-dihydroisobenzofuran-1-carboxylate
- 1 October 2012
- Published by Elsevier in Tetrahedron Letters
- Vol. 53 (41) , 5467-5470
1,4-Addition of an aryllithium reagent to diethyl ketomalonate. Scalable synthesis of ethyl 1-(hydroxymethyl)-1,3-dihydroisobenzofuran-1-carboxylate
- 1 April 2005
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 5 (3) , 257-264
Cholesteryl Ester Transfer Protein: Pharmacological Inhibition for the Modulation of Plasma Cholesterol Levels and Promising Target for the Prevention of Atherosclerosis.
Cholesteryl ester transfer protein (CETP) facilitates the exchange of neutral lipids (such as cholesteryl esters and triglycerides) between anti-atherogenic HDL particles and pro-atherogenic VLDL and LDL particles in human plasma. Individuals possessing a genetic deficiency for CETP have higher HDL cholesterol and lower LDL cholesterol and may have a reduced risk for developing cardiovascular disease. Small molecule inhibitors of CETP are being developed that would appear to provide a beneficial change in lipoprotein profile. However, randomized clinical trials are ultimately required to determine whether CETP inhibition will afford a reduction in cardiovascular events.
- 1 April 2005
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 5 (3) , 257-264
Cholesteryl Ester Transfer Protein: Pharmacological Inhibition for the Modulation of Plasma Cholesterol Levels and Promising Target for the Prevention of Atherosclerosis.
Cholesteryl ester transfer protein (CETP) facilitates the exchange of neutral lipids (such as cholesteryl esters and triglycerides) between anti-atherogenic HDL particles and pro-atherogenic VLDL and LDL particles in human plasma. Individuals possessing a genetic deficiency for CETP have higher HDL cholesterol and lower LDL cholesterol and may have a reduced risk for developing cardiovascular disease. Small molecule inhibitors of CETP are being developed that would appear to provide a beneficial change in lipoprotein profile. However, randomized clinical trials are ultimately required to determine whether CETP inhibition will afford a reduction in cardiovascular events.
- 1 May 1997
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 7 (5) , 441-455
Recent developments in the treatment of dyslipidaemia
Plasma lipids represent a major determinant for the development of coronary heart disease (CHD) and thus mortality in the industrialised world. Drug therapies that alter lipid levels have continued to demonstrate a mortality benefit in certain types of dyslipidaemia. Many enterprises are pursuing further agents that reduce the risk of CHD-events by established as well as novel mechanisms. This review provides a summary of the patents filed for such endeavours over the preceding two years.
- 1 May 1997
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 7 (5) , 441-455
Recent developments in the treatment of dyslipidaemia
Plasma lipids represent a major determinant for the development of coronary heart disease (CHD) and thus mortality in the industrialised world. Drug therapies that alter lipid levels have continued to demonstrate a mortality benefit in certain types of dyslipidaemia. Many enterprises are pursuing further agents that reduce the risk of CHD-events by established as well as novel mechanisms. This review provides a summary of the patents filed for such endeavours over the preceding two years.